Allogene Therapeutics, Inc. (ALLO)
$1.46+4.29%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $504M
- Beta
- 0.48
- P/E (TTM)
- -2.18
- Short % float
- 21.37%
- Days to cover
- 9.0
- SI change
- -6.7%
- 1W
- -2.67%
- 1M
- -17.05%
- vs SPY 1W
- -3.83%
- vs SPY 1M
- -20.04%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on ALLO?
- LOPJLB’s latest quantitative signal on Allogene Therapeutics, Inc. (ALLO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ALLO in?
- Allogene Therapeutics, Inc. (ALLO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Allogene Therapeutics, Inc. (ALLO) do?
- Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prep…